Primary-source record
Decision-gradeTopline results
Amgen Positive Phase 3 Topline for Dazodalibep in Sjögren's Disease
Amgen reported positive Phase 3 topline results for dazodalibep in moderate-to-severe systemic Sjögren's disease. The drug met the primary endpoint with statistically significant and clinically meaningful improvement in systemic disease activity.
Key facts
- Filed
- Sep 22, 2026, 09:00 PM
- Event
- Topline results
- Direction
- Positive
- Company
AMGNAmgen- Asset
- dazodalibep
- Source
- Company press release
- Confidence
- Sourced
Source excerpt
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE Dazodalibep Demonstrated Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity Results Support the Potential for a New, Highly Differentiated Treatment Option for People Living With a Debilitating Autoimmune Disease THOUSAND OAKS, Calif., Sept. 22,...